Hasle H, Rose C
Odense Sygehus, afdeling for onkologi og haematologi.
Ugeskr Laeger. 1991 Jan 28;153(5):343-6.
Alkoxyglycerol derived from shark liver oil is marketed in Denmark and mentioned in popular articles as a supplementary agent in the treatment of cancer. A questionnaire investigation carried out in the Department of Oncology and Haematology in Odense Hospital revealed that approximately 1/3 of the patients in active neoplastic therapy employed shark liver oil preparations. The clinical investigations of alkoxyglycerol were all carried out on patients with cancer of the uterine cervix. All of the investigations were carried out by the same Swedish research group. Only a minority of the experimental material was blinded. No documentation was found for inhibited tumour growth or reduced mortality resulting from treatment with alkoxyglycerol. The number of cases of irradiation damage were found to be fewer in the groups treated with alkoxyglycerol, but the difference may be partially explained by different subdivision into stages. Alkoxyglycerol results in increase in the leukocyte and thrombocyte counts while higher or lower doses have, apparently, the opposite effect. The available literature concerning the clinical effect of alkoxyglycerol is limited and unsystematic and does not support the employment of alkocyglycerol in the treatment of cancer.
源自鲨鱼肝油的烷氧基甘油在丹麦上市,并在通俗文章中被提及为癌症治疗的辅助剂。在欧登塞医院肿瘤学和血液学系进行的一项问卷调查显示,约三分之一正在接受积极肿瘤治疗的患者使用鲨鱼肝油制剂。对烷氧基甘油的临床研究均在子宫颈癌患者身上进行。所有研究均由同一个瑞典研究小组开展。仅有少数实验材料采用了盲法。未发现有文件证明烷氧基甘油治疗可抑制肿瘤生长或降低死亡率。发现接受烷氧基甘油治疗的组中放射损伤病例较少,但这种差异部分可能是由于分期不同所致。烷氧基甘油会导致白细胞和血小板计数增加,而较高或较低剂量显然会产生相反的效果。关于烷氧基甘油临床效果的现有文献有限且不系统,不支持将其用于癌症治疗。